Search Results 321-330 of 23961 for prostate cancer

  1. Jack R. Andrews, M.D. - Mayo Clinic Faculty Profiles

    ... prostate cancer, expanding active surveillance and biomarker development. PSMA therapy uses a radioactive material to kill prostate cancer cells.

  2. Nilutamide (oral route) - Mayo Clinic

    Nilutamide is used with surgery to treat metastatic prostate cancer (cancer that has spread) in men. Nilutamide belongs to the group of medicines called ...

  3. Once-daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. - Mayo Clinic

    Once-daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. · More about research at Mayo Clinic.

  4. Publications - Parminder Singh, M.D. - Mayo Clinic

    ... prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep; 25 (3):479-483 Epub 2021 July 22. View PubMed; Liu AJ, Kosiorek HE, Ueberroth BE, Jaeger E, Ledet E ...

  5. Publications - Elisabeth I. Heath, M.D. - Mayo Clinic

    Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes. Prostate Cancer Prostatic Dis. 2024 Feb 28. [Epub ahead of print]

  6. A Study to Identify Genetic Markers in Non-Cancerous Prostate Tissues, and Compare to Better Identify the Markers Unique to Prostate Cancer - Mayo Clinic

    ... prostate cancer tissue. This will provide data that can be used to identify genetic marker profiles to diagnose and provide prognosis for prostate cancer.

  7. Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer - Mayo Clinic

    Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. ... prostate cancer. Drugs used in chemotherapy work in different ways to ...

  8. FDA approves earlier use of lutetium Lu 177 vipivotide tetraxetan for patients with PSMA-positive metastatic castration-resistant prostate cancer - Mayo Clinic

    ... prostate cancer. Aug. 20, 2025. Since 2022, lutetium Lu 177 vipivotide tetraxetan has been used to treat prostate-specific membrane antigen (PSMA)-positive ...

  9. Cancer Resource Center - Medical Professionals - Mayo Clinic

    ... prostate cancer. The FDA recently expanded the indication of lutetium Lu 177 vipivotide tetraxetan for PSMA-positive metastatic castration-resistant prostate ...

  10. A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP) - Mayo Clinic

    A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate ...